New heart mapping tech tested for AFib treatment

NCT ID NCT06175234

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new mapping feature (FARAVIEW™) used with a pulsed field ablation catheter (FARAWAVE NAV™) to treat atrial fibrillation. Fifty patients with symptomatic AFib that didn't respond to medication were included. The goal was to see how well doctors could isolate the pulmonary veins and how they rated the technology. The study is complete and focused on procedure success and user feedback.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FARAWAVE NAV pulsed field ablation catheter and FARAVIEW™ mapping technology
What this could lead to
If successful, this could improve how doctors treat atrial fibrillation by making ablation procedures more precise and easier to perform.
What could go wrong
This is a small, completed study focused on user experience, not long-term patient outcomes. The technology may not work better than existing methods, and there are standard risks like bleeding or heart damage from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clínica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

  • Mater Private Hospital

    Dublin, 7 D07 RD8P, Ireland

  • Na Homolce Hospital

    Prague, 15030, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.